Retinal Vein Occlusion Treatment Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, Segmented By Disease Type (Central Retinal Vein Occlusion (CRVO), Branch Retinal Vein Occlusion (BRVO)), By Treatment (Anti-vascular Endothelial Growth Factor (Anti-VEGF), Corticosteroid Drugs, Others), By End-user (Hospital & Clinics, Retail Pharmacy, Others) Region and Competition, 2021-2031F

Forecast Period	2027-2031
Market Size (2025)	USD 3.13 Billion
CAGR (2026-2031)	6.93%
Fastest Growing Segment	Hospital & Clinics
Largest Market	North America
Market Size (2031)	USD 4.68 Billion

Market Overview

The Global Retinal Vein Occlusion Treatment Market will grow from USD 3.13 Billion in 2025 to USD 4.68 Billion by 2031 at a 6.93% CAGR. The Global Retinal Vein Occlusion Treatment Market encompasses pharmacotherapies, primarily anti-vascular endothelial growth factor (anti-VEGF) agents and corticosteroid implants, designed to reduce macular edema and improve visual acuity in patients suffering from thrombotic retinal blockages. The market’s expansion is fundamentally supported by the aging global population and the rising prevalence of lifestyle-associated risk factors such as hypertension, diabetes mellitus, and cardiovascular disorders, which significantly increase the incidence of retinal vascular events.

However, market growth is tempered by the substantial treatment burden associated with chronic therapy, which often requires repeated clinical visits. According to the American Academy of Ophthalmology, in 2025, a prospective analysis reported that the 10-year incidence of branch retinal vein occlusion was 0.64%, underscoring the persistent, long-term demand for therapeutic intervention. Despite this clinical need, the requirement for frequent intravitreal injections presents a significant challenge, as patient fatigue and non-compliance can limit the effective uptake and continuity of these treatments.

Key Market Drivers

The escalating prevalence of lifestyle-related comorbidities, particularly diabetes and hypertension, alongside an expanding global geriatric population, stands as a primary catalyst for the retinal vein occlusion treatment market. These systemic health issues significantly compromise retinal vascular integrity, leading to a higher incidence of thrombotic events that necessitate therapeutic intervention. As the patient pool susceptible to these vascular disorders grows, there is a consequential rise in the demand for effective pharmacotherapies to manage vision-threatening complications like macular edema. This surge in clinical demand is reflected in the financial performance of leading therapeutics; according to Regeneron Pharmaceuticals, October 2025, in the 'Third Quarter 2025 Financial and Operating Results', U.S. net sales of Eylea HD increased 10% to $431 million, driven by higher sales volumes and rising demand following its approval for retinal vein occlusion.

Simultaneously, the widespread adoption of advanced anti-VEGF and corticosteroid therapeutics, coupled with a robust pipeline of novel biosimilars, is reshaping market dynamics by addressing the critical need for reduced treatment burden. Clinicians and patients are increasingly prioritizing next-generation agents that offer extended durability, thereby reducing the frequency of invasive intravitreal injections and improving long-term compliance. This transition toward higher-efficacy treatments is evident in product uptake data; according to Bayer, November 2025, in the 'Third Quarter 2025 Financial Report', the new high-strength formulation of aflibercept has rapidly gained traction, now accounting for more than a quarter of the product’s total sales mix. This competitive shift is further underscored by the broader market momentum, where according to Roche, July 2025, sales of the bispecific antibody Vabysmo surged 18% to CHF 2.1 billion in the first half of the year, highlighting the aggressive expansion of the innovative retinal therapy segment.

Download Free Sample Report

Key Market Challenges

The substantial treatment burden inherent in chronic anti-VEGF therapy presents a formidable obstacle to the expansion of the Global Retinal Vein Occlusion Treatment Market. While pharmacotherapies offer functional improvements, the necessity for frequent intravitreal injections creates a logistical and psychological strain on patients, leading to injection fatigue. This regimen typically requires monthly or bimonthly clinical visits, which disrupts daily life and incurs significant indirect costs for caregivers. Consequently, this high burden acts as a ceiling on market volume by driving non-compliance and treatment discontinuation, thereby reducing the total number of administered doses.

This discontinuity severely impacts market revenue potential, as therapeutic consistency is essential for sustained commercial growth. When patients fail to adhere to the rigorous schedule, visual outcomes often deteriorate, leading to further withdrawal from care and a shrinking active patient pool. Data highlights the severity of this attrition; according to the American Society of Retina Specialists, in 2025, 63% of surveyed specialists reported patient loss to follow-up due to treatment access and burden challenges. Such high rates of drop-out demonstrate how non-compliance, driven by the demanding nature of current delivery methods, directly erodes the addressable market size.

Key Market Trends

The Global Retinal Vein Occlusion Treatment Market is undergoing a significant transformation through the Shift Toward Extended-Duration Anti-VEGF Dosing Regimens, which aims to transcend the limitations of current quarterly maintenance schedules. This trend is characterized by the development of novel antibody biopolymer conjugates designed to maintain therapeutic intraocular concentrations for significantly longer periods, thereby addressing the critical challenge of patient non-compliance due to injection fatigue. Unlike established high-dose therapies, these next-generation agents are engineering durability directly into the molecular structure to enable biannual dosing without compromising visual gains. This potential for a six-month treatment interval was substantiated by Kodiak Sciences, March 2025, in the 'Pipeline Presentation', which reported that in the Phase 3 BEACON study for retinal vein occlusion, approximately half of the patients treated with tarcocimab tedromer remained injection-free during the second six-month period of the trial, effectively doubling the durability of standard-of-care agents.

Concurrently, the Market Penetration of Cost-Effective Anti-VEGF Biosimilars is fundamentally reshaping the economic landscape of retinal care by dismantling the pricing monopoly of branded biologics. As patent cliffs for legacy anti-VEGF agents materialize, healthcare systems are aggressively integrating interchangeable biosimilars to manage the escalating costs of treating chronic retinal vascular diseases. This shift is not merely regulatory but is driving substantial commercial volume as payers and providers prioritize fiscally sustainable therapeutic options that offer equivalent clinical efficacy. The velocity of this market expansion is evident in recent financial performance; according to Sandoz, October 2025, in the 'Nine Month 2025 Sales Announcement', net sales of the company’s biosimilars portfolio, which includes key ophthalmic assets, grew 12% in constant currencies, with biosimilars now accounting for 31% of the company's total third-quarter net sales, signaling a robust acceptance of these cost-efficient alternatives in clinical practice.

Segmental Insights

The Hospital & Clinics segment is emerging as the fastest-growing component of the Global Retinal Vein Occlusion Treatment Market. This rapid expansion is principally driven by the concentration of essential diagnostic resources and therapeutic capabilities, such as intravitreal injections, within these institutions. As the prevalence of risk factors like hypertension and diabetes rises globally, patients increasingly require the multidisciplinary care models that hospitals and clinics uniquely provide. Additionally, these facilities often benefit from established reimbursement frameworks that facilitate patient access to long-term disease management, thereby securing their status as the primary setting for treating complex retinal conditions.

Regional Insights

North America leads the global retinal vein occlusion treatment market primarily due to a well-established healthcare infrastructure and a high prevalence of target retinal disorders. The region benefits from the active presence of major pharmaceutical companies driving research and product availability. Additionally, favorable reimbursement policies and prompt product approvals by the U.S. Food and Drug Administration facilitate the widespread adoption of therapies such as anti-VEGF injections. These factors, combined with increasing awareness regarding eye health management, ensure sustained market dominance in this region.

Recent Developments

• In December 2024, Regeneron Pharmaceuticals announced positive topline results from the Phase 3 QUASAR clinical trial evaluating Eylea HD (aflibercept) injection 8 mg for the treatment of macular edema secondary to retinal vein occlusion. The study met its primary endpoint, demonstrating that patients receiving the high-dose formulation every eight weeks, following an initial monthly dosing period, achieved non-inferior gains in best-corrected visual acuity compared to those receiving the standard 2 mg dose every four weeks. These findings highlighted the potential for the high-dose regimen to significantly reduce the injection burden for patients managing this retinal condition.
• In July 2024, Roche announced that the European Commission granted approval for Vabysmo (faricimab) for the treatment of visual impairment caused by macular edema secondary to retinal vein occlusion. This authorization encompassed both branch and central retinal vein occlusion, establishing the drug as the first bispecific antibody approved for this indication in the European Union. The regulatory decision was supported by results from the Phase III BALATON and COMINO studies, which demonstrated that the therapy achieved non-inferior vision gains compared to aflibercept and allowed many patients to extend their treatment intervals up to four months.
• In June 2024, Alvotech announced a strategic partnership with Advanz Pharma regarding the commercialization of AVT29, a biosimilar candidate to aflibercept, across Europe. The collaboration agreement granted Advanz Pharma exclusive rights to market the proposed biosimilar, which targets the vascular endothelial growth factor pathway involved in conditions such as retinal vein occlusion. This business development move was designed to leverage Advanz Pharma's existing commercial infrastructure in the region, aiming to accelerate the future availability of the biosimilar treatment for patients suffering from retinal diseases once regulatory requirements are met.
• In February 2024, Samsung Bioepis obtained marketing authorization from the Ministry of Food and Drug Safety in South Korea for Afilivu, a biosimilar to aflibercept. This regulatory approval covered the treatment of intraocular diseases, including macular edema secondary to retinal vein occlusion, as well as neovascular age-related macular degeneration and diabetic macular edema. The company highlighted that this milestone marked the first approval of an aflibercept biosimilar in the country, offering a new therapeutic option that could expand patient access to biologic treatments for retinal vascular disorders that cause visual impairment.

Key Market Players

• AbbVie Inc.
• F. Hoffmann-La Roche Ltd.
• Regeneron Pharmaceuticals Inc.
• Taiwan Liposome Company, Ltd.
• Aerie Pharmaceuticals Inc.
• CalciMedica Inc.
• Outlook Therapeutics, Inc.
• Kodiak Sciences Inc.
• Chugai Pharmaceutical Co., Ltd.
• Pfizer Inc.

By Disease Type	By Treatment	By End-user	By Region
Central Retinal Vein Occlusion (CRVO) Branch Retinal Vein Occlusion (BRVO)	Anti-vascular Endothelial Growth Factor (Anti-VEGF) Corticosteroid Drugs Others	Hospital & Clinics Retail Pharmacy Others	North America Europe Asia Pacific South America Middle East & Africa

Report Scope:

In this report, the Global Retinal Vein Occlusion Treatment Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

• Retinal Vein Occlusion Treatment Market, By Disease Type:

• Central Retinal Vein Occlusion (CRVO)
• Branch Retinal Vein Occlusion (BRVO)

• Retinal Vein Occlusion Treatment Market, By Treatment:

• Anti-vascular Endothelial Growth Factor (Anti-VEGF)
• Corticosteroid Drugs
• Others

• Retinal Vein Occlusion Treatment Market, By End-user:

• Hospital & Clinics
• Retail Pharmacy
• Others

• Retinal Vein Occlusion Treatment Market, By Region:

• North America
• United States
• Canada
• Mexico
• Europe
• France
• United Kingdom
• Italy
• Germany
• Spain
• Asia Pacific
• China
• India
• Japan
• Australia
• South Korea
• South America
• Brazil
• Argentina
• Colombia
• Middle East & Africa
• South Africa
• Saudi Arabia
• UAE